Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. Electronic address: lararay@psych.ucla.edu.
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: cberge21@jhmi.edu.
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Our incomplete understanding of the causes and pathways involved in the onset and progression of multiple sclerosis (MS) limits our ability to effectively treat this complex neurological disease. Rece...
Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in ad...
To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS....
We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies....
All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approv...
We used standard methodological procedures expected by Cochrane....
Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo a...
For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certai...
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ...
To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS....
We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022....
We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in...
We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s...
We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e...
Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according t...
Tuberous sclerosis (TS) is a monogenic disorder which causes disabling neurological symptoms. Similarly, multiple sclerosis (MS) may result in disability, but in contrast, is diagnosed without genetic...
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS)....
MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues....
The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to ...
A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional ana...
The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices....
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas ...
Changes in the immune system associated with ageing are known as immunosenescence. This is characterised by a decline in immune response, chronic inflammation and an increased risk of autoimmune disea...
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...